Ciclosporin in Autoimmune Diseases — Side Effects (with Emphasis on Renal Dysfunction) and Recommendations for Use

  • B. von Graffenried
  • W. B. Harrison


Based on theoretical considerations, results of animal studies in various autoimmune disease models and anecdotal experience in patients [3], a systematic clinical research programme of ciclosporin (CyA) treatment in various autoimmune diseases was undertaken in 1982. About 1000 patients have since been treated with CyA, and the side-effect profile is emerging.


Primary Biliary Cirrhosis Uveitis Posterior Papillary Adenoma Serum Creati Autoimmune Disease Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adu D, Tumey J, Michael J, et al. (1983) Hyperkalaemia in cyclosporin-treated renal allograft recipients. Lancet II:370CrossRefGoogle Scholar
  2. 2.
    Bennet WM, Pulliam JP (1983) Cyclosporine nephrotoxicity. Ann Intern Med 99:851Google Scholar
  3. 3.
    Borel JF, von Graffenried B (1984) Sand-immun (cyclosporin A) and autoimmunity. In• Lambert PH, Perrin L, Izui S (eds) Recent Advances in SLE. Academic Press, London, p 313Google Scholar
  4. 4.
    Chapman JF, Griffiths D, Harding NGL, et al. (1985) Reversibility of cyclosporin nephrotoxicity after three months’ treatment. Lancet I:128CrossRefGoogle Scholar
  5. 5.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creati-nine. Nephron 16:31PubMedCrossRefGoogle Scholar
  6. 6.
    Dunn MJ (1984) Nonsteroidal anti-inflammatory drugs and renal function. An-nu Rev Med 35:411CrossRefGoogle Scholar
  7. 7.
    Gutsche HU, Delz E, Luneburg M, et al. (1984) Effect of cyclosporine on the proximal tubular function of the rat kidney. IXth Int. Congress of Nephrology, Los Angeles, June 1984, Abstract, 475AGoogle Scholar
  8. 8.
    Kahan BD, van Buren CT, Lin S, et al. (1982) Immunopharmacologic monitoring of cyclosporin A-treated recipients of cadaveric. kidney allografts. Transplantation 34:36PubMedCrossRefGoogle Scholar
  9. 9.
    Marbet UA, Graf U, Mihatsch MJ (1980) Renale Nebenwirkungen der Therapie mit Cyclosporin A bei chronischer Polyarthritis und nach Knochenmarkstransplantation. Schweiz Med Wochenschr 110:2017PubMedGoogle Scholar
  10. 10.
    Mihatsch MJ, Thiel G, Spichtin HP, et al. (1983) Morphological findings in kidney transplants after treatment with cyclospor- ine. Transplant Proc 15:2821Google Scholar
  11. 11.
    Myers BD, Ross J, Newton L, et al. (1984) Cyclosporine-associated chronic nephropathy N Engl J Med 311:699Google Scholar
  12. 12.
    Neild GH, Rocchi G, Imbert L, et al. (1984) Effect of cyclosporine on prostacyclin synthesis by vascular tissue in rabbits. In:Kahan BD (ed) Cyclosporine. Grune and Stratton, Orlando, p 182Google Scholar
  13. 13.
    Palestine AG, Nussenblatt RB, Chan CC (1984) Side effects of systemic cyclosporine in patients not undergoing transplantation Am J Med 77:652PubMedGoogle Scholar
  14. 14.
    Puttick L, Pollock A, Fairbum E (1983) Treatment of Sézary syndrome with Cyclos-porin A. J Soc Med 76:1063CrossRefGoogle Scholar
  15. 15.
    Stiller CR, Dupré J, Gent M, et al. (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.. Science 223:1362PubMedCrossRefGoogle Scholar
  16. 16.
    Verani RR, Flechner SM, van Buren CT, et al. (1984) Acute cellular rejection or cyclosporine nephrotoxicity? A review of transplant renal biopsies. Am j Kidney Dis 4:185PubMedGoogle Scholar

Copyright information

© Sandoz Ltd, Basle 1985

Authors and Affiliations

  • B. von Graffenried
    • 1
  • W. B. Harrison
    • 2
  1. 1.Clinical Research DepartmentSandoz LtdBasleSwitzerland
  2. 2.Published with kind permission of Grune and StrattonOrlandoUSA

Personalised recommendations